Hepatic Enzyme Abnormalities and Their Association With Hematological Parameters in Sickle Cell Disease: A Case‐Control Study in Cameroon Authors: Josué Louokdom Simo, Prisca Tipane Angandji, Romaric De Manfouo Tuono, Kabrel Fandouo Njinjou, Ingrid Worti Sulem Yong, Maryline Seuko Njopwouo, Pascal Dieudonne Djamen Chuisseu Published: 2026 ABSTRACT ABSTRACTBackground and AimsThe polymerization of deoxygenated hemoglobin S, resulting from a genetic mutation in sickle cell disease (SCD), leads to damage in multiple organs, including renal, cardiopulmonary, and cerebrovascular systems. The liver is also commonly affected, resulting in “sickle cell liver disease,” which may lead to progressive fibrosis and impaired liver function in adulthood. We hypothesized that hepatic enzyme abnormalities are frequent in patients with sickle cell disease and are associated with underlying hematological alterations related to hemolysis. This study aimed to determine the frequency of hepatic enzyme abnormalities in patients with sickle cell disease and to examine their association with hematological parameters.MethodsA 4‐month case‐control study was conducted at the Hematology Department of the Bafoussam Regional Hospital. Following informed consent, blood samples were collected in EDTA tubes for complete blood counts (performed by flow cytometry) and in plain tubes for biochemical analyses. These included the enzymatic activities of alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma‐glutamyl transferase (GGT), measured using kinetic spectrophotometric methods, as well as albumin concentration, determined using a colorimetric spectrophotometric method. Based on these biochemical parameters, patterns of hepatocellular injury, cholestasis, and mixed liver injury were identified. Data were analyzed using R software version 4.1.1.ResultsA total of 167 participants were enrolled, including 94 patients with homozygous sickle cell disease (SS) and 73 healthy controls (AA). ALT levels were significantly higher in patients than in controls, with median values of 18.2 U/L [14.0–26.7] versus 15.1 U/L [12.0–24.0] (p = 0.007). AST levels were also significantly elevated in patients, with 68 (72.3%) showing increased values compared to none among controls (p < 0.001). Similarly, ALP levels were higher in patients, with 60 (63.8%) presenting elevated values compared to none in controls (p < 0.001). GGT levels were significantly increased in patients compared to controls, with median values of 42.0 U/L [35.0–52.2] versus 27.0 U/L [24.0–30.0] (p < 0.001). Albumin levels were significantly lower in patients, with 36 (38.3%) exhibiting hypoalbuminemia compared to none in controls (p < 0.001). Furthermore, biochemical suspicion of cholestatic injury was significantly more frequent in patients (23.4%) than in controls (0%) (p < 0.001), while 8 (8.5%) patients showed biochemical suspicion of hepatocellular injury compared to none in controls (p = 0.01).ConclusionThese findings indicate significant liver involvement in patients with sickle cell disease, characterized by hepatocellular injury, cholestasis, and impaired synthetic function. Regular biochemical monitoring of liver function is therefore essential to improve disease management and prevent complications.Keywords: blood count profile, Cameroon, hepatocellular function, sickle cell disease Introduction Sickle cell disease (SCD) is one of the most common genetic disorders worldwide, particularly in Africa [1]. It is estimated that 5% of the global population carries genes for hemoglobin disorders, with SCD being the most prevalent [1, 2, 3]. The prevalence of sickle cell genes in sub‐Saharan Africa is especially high, reaching approximately 20%–30% [1]. SCD is a major contributor to mortality across all age groups; in Cameroon, for example, it is responsible for an estimated 400 deaths annually, highlighting the severity of the disease [4, 5]. At the cellular and molecular level, SCD is an autosomal recessive disorder caused by a point mutation in the β‐globin gene on the short arm of chromosome 11, where glutamic acid is replaced by valine at position 6 of the β‐globin chain [6, 7]. This mutation results in the production of hemoglobin S, which polymerizes under deoxygenated conditions, leading to reduced red blood cell elasticity, increased rigidity, and damage to the vascular endothelium. These changes trigger vaso‐occlusive crises, arising from a cascade of pathological events including infarction, hemolysis, inflammation, hypercoagulability, and oxidative stress [8, 9, 10, 11]. Consequently, multiple organs are affected, causing renal, cardiopulmonary, and cerebrovascular complications (particularly in children) [12, 13]. The liver is also frequently affected, giving rise to a spectrum of complications collectively termed “sickle hepatopathy” [14, 15, 16]. Despite the multisystemic impact of SCD, the natural history of liver disease in this context is not well characterized, and hepatic involvement is often overlooked. Nonetheless, the clinical significance is underscored by morbidity and mortality rates attributed to hepatocellular damage, reported to range from 6% to 11% [14, 17, 18]. Previous studies have estimated the prevalence of liver dysfunction in SCD at approximately 10%, with an associated mortality of 7% [14, 19]. Hepatobiliary complications, most commonly gallstones, affect up to 37% of children with SCD, suggesting that liver‐related conditions may appear early in life and worsen over time [16]. SCD can lead to progressive liver injury, resulting in significant fibrosis and reduced liver function by adulthood [20, 21, 22]. Tissue ischemia during vaso‐occlusive episodes causes hepatocyte lysis, contributing to multi‐organ involvement and explaining several clinical manifestations of SCD [22, 23, 24]. Kupffer cell hyperplasia and erythrophagocytosis observed during crises further impair hepatocellular integrity [14, 18, 25]. These pathophysiological processes manifest as measurable alterations in liver function, including reduced detoxification and synthetic capacity, detectable through biochemical biomarkers [26, 27, 28]. Even asymptomatic patients may exhibit hepatomegaly and elevated liver enzymes [22, 23, 24]. Abnormalities in liver function among SCD patients are multifactorial in origin. Despite their potential severity, these disorders often remain underrecognized in clinical practice, posing challenges for effective management. The absence of systematic assessment and targeted management represents a significant gap in monitoring the SCD population. We hypothesized that hepatic enzyme abnormalities are frequent in patients with sickle cell disease and are associated with hematological alterations related to hemolysis. Despite the high burden of SCD in sub‐Saharan Africa, there is limited data examining the relationship between hepatocellular biomarkers and hematological parameters to characterize patterns of liver dysfunction in this population. This study aims to assess the frequency of liver enzyme abnormalities in patients with SCD and to examine their association with hematological parameters. By jointly evaluating hepatic and hematological profiles, this study seeks to provide a clearer description of liver dysfunction in patients with sickle cell disease. Methods Ethical Considerations This study was conducted in accordance with the ethical principles of medical and scientific research as outlined in the Declaration of Helsinki [29]. Ethical approval (No. 2025/236/UdM/PR/CEAQ) was granted by the Institutional Ethics and Research Committee of the University of the Mountains (UdM). Authorization for data collection was subsequently obtained from the Director of the Regional Hospital of Bafoussam (No. 470/L/MINSANTE/SG/DRSPO/HRB/D). All participants were fully informed about the study's purpose, objectives, potential benefits, and possible risks. Free and informed consent was obtained from each participant, translated into the local language when necessary, and formalized by signature. Confidentiality was strictly maintained for all collected data. Study Design and Study Population We conducted an analytical case‐control study over a period of 4 months at the Bafoussam Regional Hospital, a second‐level hospital in Cameroon's health system offering nearly all medical specialties and serving patients from the region and surrounding areas. The hospital's Department of Medicine and Clinical Hematology enabled the recruitment of sickle cell patients for this study. Participants of all ages and both sexes were recruited consecutively. Sickle cell patients were included only if they were in a steady‐state condition, defined as “a period free of crisis extending from at least 3 weeks since the last clinical event and 3 months or more since the last blood transfusion, up to at least 1 week before the onset of a new clinical event” [30]. Controls of apparently good health were recruited from the same environment and were frequency‐matched to cases by age and sex. Individual matching was performed, and analyses were adjusted accordingly. A pre‐established questionnaire was used to collect information from all participants, including sociodemographic characteristics, patient‐specific factors (such as the presence of a sibling with sickle cell disease), date of diagnosis, date of the last blood transfusion, date of the last vaso‐occlusive crisis (VOC), presence of comorbidities, current medications, and dietary habits. Participants were serologically screened for HBsAg and anti‐HCV antibodies prior to inclusion. Exclusion criteria included smoking, frequent alcohol consumption, recent high‐fat diet, use of unidentified hepatotoxic drugs, any reported traditional treatment, or comorbidities, including viral infections such as HBV, HCV, or others. A total of 167 participants were ultimately retained for the study, including 94 SS sickle cell cases and 73 AA controls. Blood Samples and Biological Analyses Blood Collection Blood samples were collected from each study participant at the antecubital fossa. A total of 4 mL of blood was drawn from each participant, with samples placed in plain tubes for biochemical assays and in EDTA‐anticoagulated tubes for hematological analyses. Hematological Analysis The hemoglobin profile of each participant was first confirmed using agarose gel electrophoresis, following the protocol provided by Hellabio (Thessaloniki, Greece), including specified migration conditions, buffer system, and interpretation criteria. A complete blood count was then performed using a Mindray BC‐5000 hematology analyzer. This was followed by a systematic examination of peripheral blood smears, stained with May‐Grünwald‐Giemsa, to assess white blood cell differentials and evaluate red blood cell morphology. Reticulocyte counts were determined using vital staining with brilliant cresyl blue, allowing characterization of anemias. All staining procedures were conducted according to the Rovanowsky protocol [31]. The slides were examined under an Irmerco binocular microscope, and final interpretations were made in accordance with WHO recommendations. Hepatocellular Exploration The parameters used to assess hepatocellular function in this study included AST, ALT, ALP, GGT, and albumin. Enzymatic activities of Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), and Gamma‐Glutamyl Transferase (GGT) were measured using kinetic enzymatic methods according to Accucare protocols (Monlab, Barcelona, Spain) on a DIALAB DTN‐405 Chemistry Analyzer. Albumin concentration was subsequently determined by a colorimetric method using Monlab reagents (Barcelona, Spain) on the same DIALAB DTN‐405 Chemistry Analyzer. Based on these biochemical analyses, the following patterns were defined in accordance with previous studies [32, 33]: Hepatocellular injury was suspected when both AST and ALT were elevated. Hepatocellular injury was suspected when both AST and ALT were elevated. Cholestatic pattern was suspected when cholestasis markers (ALP and GGT) were elevated. Cholestatic pattern was suspected when cholestasis markers (ALP and GGT) were elevated. Mixed pattern was defined by simultaneous elevations of hepatocellular enzymes (AST, ALT) and cholestasis markers (ALP, GGT). Mixed pattern was defined by simultaneous elevations of hepatocellular enzymes (AST, ALT) and cholestasis markers (ALP, GGT). Hepatic synthetic dysfunction was defined by a decrease in albumin concentration relative to normal reference values [32]. Hepatic synthetic dysfunction was defined by a decrease in albumin concentration relative to normal reference values [32]. This approach allowed a systematic classification of liver function abnormalities, integrating both hepatocellular and cholestatic components for a more precise interpretation. Data Management and Statistical Analysis The hematological and biochemical parameters obtained were analyzed and interpreted according to WHO recommendations [34]. The variables included sociodemographic characteristics, clinical data, and biological parameters of the participants. Quantitative variables encompassed hematological parameters, red blood cell count, white blood cell count, platelet count, hemoglobin levels, and erythrocyte indices, as well as hepatocellular function parameters, including enzyme activities of ALT, AST, ALP, GGT, and albumin concentration. Based on these measurements, liver injury patterns were classified as hepatocellular, cholestatic, or mixed, according to biochemical criteria. The reference ranges used to define elevated values were aligned with accepted laboratory standards: Alanine aminotransferase (ALT/SGPT): 7–56 U/L Alanine aminotransferase (ALT/SGPT): 7–56 U/L Aspartate aminotransferase (AST/SGOT): 10–40 U/L Aspartate aminotransferase (AST/SGOT): 10–40 U/L Alkaline phosphatase (ALP): 45–120 U/L Alkaline phosphatase (ALP): 45–120 U/L Gamma‐glutamyl transferase (GGT): 9–48 U/L Gamma‐glutamyl transferase (GGT): 9–48 U/L Pattern definitions were as follows: Hepatocellular injury: ALT and/or AST > 2× ULN (upper limit of normal), with ALP normal or < 2× ULN Hepatocellular injury: ALT and/or AST > 2× ULN (upper limit of normal), with ALP normal or < 2× ULN Cholestatic pattern: ALP > 2× ULN, with ALT/AST normal or < 2× ULN Cholestatic pattern: ALP > 2× ULN, with ALT/AST normal or < 2× ULN Mixed pattern: both ALT/AST and ALP > 2× ULN Mixed pattern: both ALT/AST and ALP > 2× ULN Albumin was interpreted with caution as a marker of hepatic synthetic function, since its levels may be influenced by nutritional status, particularly in light of the high proportion of underweight patients. For ease of clinical interpretation, quantitative variables were dichotomized into “low, normal, high,” based on manufacturer reference values and established scientific standards. All data were recorded in an Excel 2013 spreadsheet and analyzed using R software version 4.1.1. The Smirnov–Kolmogorov test was used to assess the normality of variable distributions. Quantitative variables were presented as median and interquartile range, while qualitative variables were expressed as frequencies. Comparisons of quantitative variables were performed using the Wilcoxon test, and proportions were compared using Fisher's Exact test. Confidence intervals were calculated at 95%, and statistical significance was set at p < 0.05. Results Distribution of the Population According to Sociodemographic and Clinical‐Biological Characteristics Distribution of the Population According to Sociodemographic and Anthropometric Characteristics A total of 167 study participants were enrolled, including 94 SS sickle cell cases and 73 AA controls. Participants were recruited from the West Cameroon region and surrounding towns and villages, with the majority belonging to the Bamiléké ethnic group. Table 1 presents the sociodemographic and anthropometric characteristics of the study population. Table 1Sociodemographic and anthropometric characteristics of participants.VariablesParametersCases N = 94 n (%)Controls N = 73 n (%)Total N = 167 n (%) p valueSexFemale32 (34.0)49 (67.1)81 (48.5)< 0.001 a ,* Male62 (66.0)24 (32.9)86 (51.5)Age, med IQR11.0 [6.00–16.0]12.0 [6.00–20.0]11.0 [6.00–17.0]0.51 b BMI, med IQR17.4 [15.6–19.2]19.5 [18.8–20.8]18.8 [17.0–20.0]< 0.001 a ,* BMIUnderweight54 (57.4)0 (0.00)54 (32.3)< 0.001 a ,* Normal40 (42.6)73 (100)113 (67.7) Note: Age (in years), med [q1–q3] = median and interquartile range, n (%) = effectives; (frequencies). aFisher's exact test. bWilcoxon test.*Significant test at p < 0.05. Sociodemographic and anthropometric characteristics of participants. Note: Age (in years), med [q1–q3] = median and interquartile range, n (%) = effectives; (frequencies). aFisher's exact test. bWilcoxon test. Significant test at p < 0.05. Table 1 shows that male SCD patients accounted for 62 (66.0%) of cases, while females represented 32 (34.0%), resulting in a sex ratio of 2. In the overall study population, 51.5% were male and 48.5% were female. Participants were predominantly young, with a median age of 11.0 years [6.0–16.0] in patients and 12.0 years [6.0–20.0] in controls. Furthermore, body mass index differed significantly between patients and controls, with a notably high proportion of underweight SCD patients (57.4%, p < 0.001). Distribution of the Sickle Cell Population According to Their Clinical History and Lifestyle The included patients had a recent history of vaso‐occlusive crises (VOCs) and received regular blood transfusions, with previous transfusions occurring on average 1 ± 0.2 years prior. Participants also presented with histories of infectious crises, anemic crises, cardiovascular disease, and stroke. Hydroxyurea use was recorded, and the average frequency of VOCs was approximately one episode per month. Disease duration and transfusion history were documented for all participants. Dietary intake was varied, including fruits, vegetables, and meats. Table 2 summarizes selected clinical histories of the patients. Table 2Patient history and clinical characteristics.VariablesParametersEffectives N = 94 (n)%Abdominal painNo6670.2Yes2829.8Acute thoracic syndromeNo6266Yes3234JaundiceNo7074.5Yes2425.5ABO and Rh blood groupO+3840.28A+2627.7AB+1819.1B+1212.8 Note: n = effective, % = frequency. Patient history and clinical characteristics. Note: n = effective, % = frequency. Table 2 shows that 32 (34.0%) patients presented with acute chest syndrome, while 24 (25.5%) exhibited jaundice. Additionally, the most common blood group among the participants was O positive (40.3%). Distribution of the Study Population According to Biological Parameters Blood Count Profile Profile of the Red Line in Sickle Cell Disease Table 3 shows that 84 (89.4%) patients had low hemoglobin levels. Additionally, 42 (44.7%) exhibited microcytosis, and 40 (42.6%) presented with hypochromia, with a mean MCH of 27.58 ± 4.33 pg. Low MCHC was observed in 5 (11.1%) patients. Most cases of anemia were regenerative, as indicated by elevated reticulocyte counts in 89.4% of patients. Table 3Red lineage profile in sickle cell patients.VariablesParametersEffective (N = 94) (n)Total (%)Red blood cellsLow8287.2High22.13Normal1010.6Red blood cells (T/L), med IQR2.70 [2.36–3.10]HemoglobinLow8489.4Normal1010.6Hemoglobin (g/L), med IQR7.60 [6.78–8.28]HematocritLow8489.4High22.13Normal88.51Hematocrit (%), med [q1–q3]22.1 [19.5–23.9]MCVLow4244.7Normal5255.3MCV (fL), med IQR80.0 [74.0–86.0]MCHLow4042.6Normal5457.4MCH (pg/c), med IQR27.8 [25.0–31.0]MCHCLow1010.6Normal8489.4MCHC (g/L), med IQR35.3 [33.6–36.1]ReticulocytesHigh8489.4Normal1010.6Reticulocytes (G/L), med [q1–q3]355 [275–379.2] Note: Med [q1–q3] = median and interquartile range, n (%) = effective (frequencies).Abbreviations: MCHC, mean corpuscular hemoglobin concentration; MCHC, mean corpuscular hemoglobin content; MCV, mean corpuscular volume. Red lineage profile in sickle cell patients. Note: Med [q1–q3] = median and interquartile range, n (%) = effective (frequencies). Abbreviations: MCHC, mean corpuscular hemoglobin concentration; MCHC, mean corpuscular hemoglobin content; MCV, mean corpuscular volume. White Blood Cell and Platelet Profile in Sickle Cell Patients The following Table 4 describes the white blood cell and platelet profile in sickle cell patients. Table 4White blood cell and platelet profile in sickle cell patients.VariablesParametersEffective (N = 94) (n)Total (%)White blood cellsHigh7883.0Normal1617.0White blood cells (G/L), med IQR15.8 [12.5–1]LymphocytesHigh7276.6Normal2223.4Lymphocytes (G/L), med IQR6.1 [4.2–9.1]MonocytesHigh94100Monocytes (G/L), med IQR2.4 [1.6–3.1]GranulocytesHigh4042.6Normal5457.4Granulocytes (G/L), med IQR6.6 [4.7–8.6]PlateletsLow44.26High6468.1Normal2627.7Platelets (G/L), med IQR532 [312–611] Note: Med IQR = median and interquartile range, n (%) = effective (frequencies). White blood cell and platelet profile in sickle cell patients. Note: Med IQR = median and interquartile range, n (%) = effective (frequencies). Table 4 shows that 78 (83.0%) patients had leukocytosis, 4 (4.3%) presented with thrombocytopenia, and 64 (68.1%) exhibited thrombocytosis. Liver Functions and Frequency of Hepatocellular Disorders Hepatocellular Exploration Table 5 below describes the profile of the liver function markers explored in the study population. Table 5Profile of liver function testing markers in participants.VariablesParametersCases N = 94 n (%)Controls N = 73 n (%)Total N = 167 n (%) p valueALT (U/L), med IQR18.2 [14.0–26.7]15.1 [12.0–24.0]16.6 [12.9–26.2]0.007 b ,* ALTHigh10 (10.6)0 (0.00)10 (5.99)0.003 a ,* Normal84 (89.4%)73 (100%)157 (94.0)AST (U/L), med IQR47.7 [33.2–65.5]21.0 [17.5–23.2]30.1 [21.4–49.2]< 0.001 b ,* ASTHigh68 (72.3)0 (0.00)68 (40.7)< 0.001 a ,* Normal26 (27.7)73 (100)99 (59.3)ALP (U/L), med IQR431 [331–552]135 [103–145]252 [135–447]< 0.001 b ,* ALPNormal34 (36.2)73 (100)107 (64.1)< 0.001 a ,* High60 (63.8)0 (0.00)60 (35.9)GGT (U/L), med IQR42.0 [35.0–52.2]27.0 [24.0–30.0]35.0 [28.0–45.0]< 0.001 b ,* GGTHigh60 (63.8)0 (0.00%)60 (35.9%)< 0.001 a ,* Normal34 (36.2)73 (100%)107 (64.1%)Albumin (g/L), med IQR37.0 [32.4–41.1]38.9 [36.9–42.1]38.1 [35.5–42.1]0.006 b ,* AlbuminLow36 (38.3)0 (0.00)36 (21.6)< 0.001 a ,* High2 (2.13)0 (0.00)2 (1.20)Normal56 (59.6)73 (100)129 (77.2) Note: Med IQR = median and interquartile range, n (%) = effective (frequencies).Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transferase. aFisher's exact test. bWilcoxon test.*Significant test at p < 0.05. Profile of liver function testing markers in participants. Note: Med IQR = median and interquartile range, n (%) = effective (frequencies). Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transferase. aFisher's exact test. bWilcoxon test. Significant test at p < 0.05. Table 5 shows that ALT activity was significantly higher in patients than in controls, with median values of 18.2 U/L [14.0–26.7] versus 15.1 U/L [12.0–24.0] (p = 0.007). AST activity was also significantly elevated in patients, with 68 (72.3%) exhibiting hyperactivity compared to none in the control group (p < 0.001). Similarly, ALP activity was higher in patients, with 60 (63.8%) showing elevated levels versus none in controls (p < 0.001). GGT activity was significantly increased in patients, with medians of 42.0 U/L [35.0–52.2] compared to 27.0 U/L [24.0–30.0] in controls (p < 0.001). Albumin concentrations were lower in patients, with 36 (38.3%) presenting low levels versus none in controls (p < 0.001). Frequency of Hepatocellular Disorders Table 6 below summarizes the frequency of hepatocellular disorders observed in participants. Table 6Frequency of hepatocellular disorders in participants.VariablesParametersCases N = 94 n (%)Controls N = 73 n (%)Total N = 167 n (%) p valueCholestatic lesionNo72 (76.6)73 (100)145 (86.8)< 0.001 a ,* Yes22 (23.4)0 (0.00)22 (13.2)Hepatocellular injuryNo86 (91.5)73 (100)159 (95.2)0.01 a ,* Yes8 (8.51)0 (0.00)8 (4.79)Mixed lesionNo90 (95.7)73 (100)163 (97.6)0.13 a Yes4 (4.26)0 (0.00)4 (2.40) Note: n (%) = effective (frequencies). aFisher's exact test.*Significant test at p < 0.05. Frequency of hepatocellular disorders in participants. Note: n (%) = effective (frequencies). aFisher's exact test. *Significant test at p < 0.05. According to Table 6, 8 (8.51%) patients presented a biochemical suspicion of hepatocellular injury compared to none in the controls (p = 0.01). Additionally, cholestatic injury was significantly more frequent in patients, occurring in 23.4% versus none in controls (p < 0.001). Finally, 4 (4.3%) patients showed a pattern suggestive of mixed liver injury, compared to none in controls, although this difference did not reach statistical significance. Discussion Sickle cell disease (SCD) is a hemoglobinopathy characterized by chronic hemolysis and vaso‐occlusive phenomena, two key mechanisms involved in hepatic injury. Therefore, the hematological abnormalities observed in our study should not be considered independent findings, but rather as direct pathophysiological determinants of hepatic alterations. Chronic hemolysis represents a central mechanism linking hematological parameters to liver function. The accelerated destruction of red blood cells leads to excessive release of free hemoglobin and bilirubin, exposing the liver to metabolic overload and promoting hyperbilirubinemia as well as hepatobiliary complications. Recent studies have shown that intravascular hemolysis is associated with heme toxicity, systemic inflammation, and multi‐organ damage, including liver injury [35]. Furthermore, classical markers of hemolysis (LDH, bilirubin, AST, reticulocytes) are interrelated and reflect the intensity of the hemolytic process [36]. Thus, parameters such as hemoglobin levels and red cell indices provide indirect insight into hemolytic burden and contribute to the interpretation of hepatic abnormalities. The hemoglobin S characteristic of SCD predisposes patients to multisystem complications, including renal, cardiopulmonary, cerebrovascular (particularly in children), and hepatic involvement. Abnormal liver function tests in SCD patients have been widely reported, notably by Schubert et al. [37]. However, the true incidence of liver disease in SCD remains difficult to determine [38], largely due to its multifactorial pathophysiology involving hemolysis, vaso‐occlusion, and other contributing factors [24], as well as the lack of well‐defined diagnostic criteria. In this context, the present study aimed to assess the frequency of liver enzyme abnormalities in patients with SCD and to examine their association with hematological parameters reflecting hemolysis. Our findings showed that 8.51% of sickle cell patients presented hepatocellular injury compared to none in the control group (p = 0.01). In addition, 23.4% of patients exhibited a cholestatic pattern, which was significantly more frequent than in controls (p < 0.001). Finally, 4.26% of patients showed a suspected mixed pattern, although this difference was not statistically significant. These abnormalities likely reflect the combined effects of hemolysis and hepatic dysfunction, as reported in previous studies [39, 40, 41]. Clinically, such disturbances may manifest as jaundice, hepatomegaly, and, in severe cases, may progress to acute hepatic decompensation or cirrhosis [42]. The sickle cell population included in this study was predominantly male (66.0%), resulting in a sex ratio of 2. This differs from the findings of Tuono et al. [43], who reported a nearly equal distribution between the sexes, as well as those of Dahmani et al. and Doupa et al. [44, 45]. However, our results are similar to those reported by Akinbami et al. in Nigeria [46]. Such differences may be attributable to geographical variations among study populations. The participants were relatively young, consistent with observations from several other studies [47, 48]. A majority were underweight, which aligns with findings reported by other authors [43, 49]. The clinical histories of the patients were characterized by recurrent vaso‐occlusive crises, hemolytic crises, acute chest syndrome, prior blood transfusions, and jaundice—features representing the characteristic profile of sickle cell patients. These observations have also been documented in previous studies [46, 48, 50]. Furthermore, the hematological profile was marked by a high frequency of anemia (89.4%), which was predominantly microcytic (44.7%), hypochromic (42.6%), and regenerative (89.4%). These findings are consistent with observations reported by several [43, 49, 51, 52, 53, 54]. Indeed, from fetal life through adulthood, sickle cell patients develop chronic hemolytic anemia that persists throughout life, occasionally punctuated by acute “anemia crises,” characterized by a rapid drop in hemoglobin levels. These hyperhemolytic crises lead to abrupt reductions in hemoglobin at steady state, accompanied by elevated reticulocyte counts [53, 54, 55, 56]. Additionally, a high prevalence of leukocytosis (83%) was observed, along with thrombocytosis in 68.1% of patients. Leukocytosis results from increased production of white blood cells by the bone marrow in response to systemic inflammation, as well as the mobilization of leukocytes stored in peripheral reservoirs. During hyperhemolytic episodes, robust bone marrow regeneration can induce erythroblastosis, which may contribute to apparent (false) hyperleukocytosis [45, 54]. Regarding platelets, thrombocytosis likely arises from enhanced bone marrow production in response to chronic anemia, compounded by functional asplenia leading to reduced splenic clearance [45, 57]. Thus, the severity of hematological abnormalities is directly associated with the severity of hepatic involvement. Recent evidence suggests that chronic hemolysis promotes the accumulation of heme and iron in the liver, leading to oxidative stress and inflammation responsible for hepatobiliary injury [58]. Furthermore, certain clinical manifestations, such as acute hepatic sequestration, are accompanied by a rapid drop in hemoglobin levels and a marked increase in bilirubin, illustrating the close link between erythrocyte dynamics and hepatic dysfunction [59]. These interactions are modulated by additional factors such as transfusion‐related iron overload, chronic inflammation, and nutritional status. All of these factors simultaneously influence both hematological and hepatic parameters, reinforcing their interdependence. It is also important to note that the severity of hemolysis and anemia independently contributes to organ dysfunction in sickle cell disease, highlighting the complexity of the underlying mechanisms [60]. In addition, specific evaluation of liver function revealed alterations in synthetic capacity among the patients, evidenced by significantly lower albumin concentrations compared to controls (p < 0.001), as well as the presence of thrombocytopenia. These findings are consistent with previous reports [61, 62, 63]. Physiologically, the liver synthesizes coagulation factors, anticoagulants, proteins involved in fibrinolysis, and thrombopoietin—a key regulator of platelet production from megakaryocytes [64, 65, 66] as well as albumin, which plays an essential role in maintaining oncotic pressure, transporting hormones, and regulating carbohydrate and lipid metabolism [20, 62]. Hepatocellular dysfunction in sickle cell disease may therefore result in impaired synthesis of these molecules, with direct consequences for hormonal, vitamin, and drug transport, as well as defective regulation of lipid and carbohydrate metabolism [61, 65]. Moreover, ALT activity was significantly higher in patients than in controls, with median values of 18.2 U/L [14.0–26.7] versus 15.1 U/L [12.0–24.0] (p = 0.007). AST activity was also significantly elevated in patients, with 68 (72.3%) exhibiting hyperactivity compared to none in controls (p < 0.001). Elevation of plasma AST reflects chronic hemolysis, whereas ALT levels indicate hepatocyte injury [24, 33]. These observations are consistent with reports by several authors [33, 42, 67]. ALP activity was significantly higher in patients, with 60 (63.8%) presenting elevated levels compared to none in controls (p < 0.001). GGT activity was also significantly increased in patients, with medians of 42.0 U/L [35.0–52.2] versus 27.0 U/L [24.0–30.0] in controls (p < 0.001). Elevated ALP levels indicate cholestasis in sickle cell patients, while increased GGT reflects hepatocellular injury. These abnormalities may result from red blood cell sickling within hepatic sinusoids during vaso‐occlusive crises, leading to intrahepatic cholestasis, or from chronic bone involvement secondary to the same crises. Thus, ALP elevations can originate from either hepatic or bone sources, depending on the predominant pathophysiological mechanism [68]. These findings are in agreement with those reported by previous studies [27, 39]. One of the limitations of these studies lies in the description and interpretation of the biological tests carried out; a histological section analysis would have allowed us to attest to the hepatocyte damage and also to evaluate the extent of the damage. The significant difference in BMI between groups may represent a potential confounder for the interpretation of liver parameters, which constitutes a limitation of our study. Another limitation is the cross‐sectional design, lack of histological confirmation, potential absence/limitations of viral screening, and lack of adjustment for confounders. Despite this, the observations and conclusions made are of great interest for the improvement of the care of sickle cell patients because they would make it possible to prevent complications related to hepatocellular diseases. Another perspective lies in factor analysis in order to identify the factors associated with liver damage in sickle cell patients. Conclusion Hemoglobin S, characteristic of sickle cell disease, predisposes patients to multi‐organ damage, including the liver. This study found significant hepatocellular abnormalities in SCD patients, with elevated ALT and AST, a cholestasis pattern (ALP and GGT), and reduced albumin synthesis. Hematological analyses also showed marked anemia and altered red cell indices, reflecting the interplay between hemolysis and liver dysfunction. These findings underscore the importance of regular monitoring of both hematological and hepatic parameters to optimize SCD management and prevent complications, and they highlight the potential value of histological evaluation to assess hepatocellular injury. Author Contributions Josué Louokdom Simo: conceptualization, writing – review and editing, and writing – original draft. Prisca Tipane Angandji: methodology and writing – original draft. Romaric De Manfouo Tuono: conceptualization, methodology, data curation, validation, formal analysis, and writing – original draft. Kabrel Fandouo Njinjou: methodology and writing – original draft. Ingrid Worti Sulem Yong: conceptualization, methodology, and writing – original draft. Maryline Seuko Njopwouo: conceptualization, methodology, and writing – original draft. Pascal Dieudonne Djamen Chuisseu: writing – review and editing, writing – original draft, and conceptualization. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The corresponding author, Romaric Tuono De Manfouo, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Acknowledgments We address our sincere thanks to all the staff of “Hopital Regional de Bafoussam” and of the Université des Montagnes for their help in carrying out this work. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.